StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
INTSBullishCorporate Developmentsnews
Medium materiality6/10

Intensity Therapeutics restarts presurgical TNBC trial in Europe; early data awaited

Jul 15, 2026, 7:47 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Restarting a halted mid-stage program and advancing enrollment creates potential near-term catalysts. If safety signals improve and pCR trends are favorable, the stock could re-rate on progress toward data milestones or potential orphan/partnering opportunities. Historical parallels show small-cap biotech re-rates on trial milestones even when definitive efficacy is not yet proven.

AI summary

What happened, with direct paths to the underlying reporting

Intensity Therapeutics has resumed the INVINCIBLE-4 presurgical TNBC study in Switzerland, dosing new patients with INT230-6 while comparing against SOC. The protocol was amended to reduce the drug-to-tumor ratio and employ a single injection to address prior skin irritation. With 14 patients treated before the pause and 47 more expected in Switzerland and France, the trial remains focused on pCR as the primary readout.

  • Intensity restarts INVINCIBLE-4 presurgical TNBC trial in Europe using INT230-6.
  • 14 patients treated pre-pause; 7 combo vs SOC; additional 47 expected.
  • Protocol amended to lower drug-to-tumor ratio and use a single injection.
  • Primary endpoint pCR vs null hypothesis pCR ≤ 0.6; SOC comparison ongoing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event